June 4, 2021
The Ministry of Health, Labor and Welfare (MHLW) on June 3 ordered a package insert revision for Novartis Pharma’s schizophrenia drug Clozaril (clozapine), by expanding blood testing intervals and relaxing criteria for re-administration. Clozaril can cause serious side effects such...read more